Canopy Growth Corp Overview
Industry: Drug Manufacturers Specialty & Generic
Sector: Healthcare
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada. Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Cons Read MoreMavefund brings filings, fundamentals, valuation, price history and news for Canopy Growth Corp into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $81.2 (reported). Net loss was -$0M. Adjusted EBITDA was $3.2.
What changed
- Revenue reported to $81.2.
Guidance / outlook
No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
Canopy Growth Corp (CGC) (Q1 2027) Earnings Call Highlights: Revenue Surges 13% and Gross ...
Headline from Yahoo Finance: Canopy Growth Corp (CGC) (Q1 2027) Earnings Call Highlights: Revenue Surges 13% and Gross .
Canopy Growth Q1 Earnings Call Highlights
Headline from Yahoo Finance: Canopy Growth Q1 Earnings Call Highlights.
Earnings call transcript: Canopy Growth posts Q1 2026 EPS beat, shares rise
Headline from Investing.com: Earnings call transcript: Canopy Growth posts Q1 2026 EPS beat, shares rise.
Earnings Week Ahead: PLTR, AMD, PFE, DIS, SHOP, VTRS, CGC, MCD, ROKU, ABNB, and more
Headline from Seeking Alpha: Earnings Week Ahead: PLTR, AMD, PFE, DIS, SHOP, VTRS, CGC, MCD, ROKU, ABNB, and more.
Canopy Growth renews EU certification for Ontario facility
Headline from Investing.com: Canopy Growth renews EU certification for Ontario facility.
Canopy Growth Secures Renewed EU GMP Certification at Kincardine as European Medical Cannabis Business Grows
Headline from Business Wire: Canopy Growth Secures Renewed EU GMP Certification at Kincardine as European Medical Cannabis Business Grows.
Earnings Per Share
Return on Equity
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.